An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia

Neuropsychopharmacology

Volumn 41, Issue 8, 2016, Pages 2052-2061

  Balu, Darrick T ^a,b   Li, Yan ^a   Takagi, Shunsuke ^b,c   Presti, Kendall Taylor ^b   Ramikie, Teniel S ^a   Rook, Jerri M ^d   Jones, Carrie K ^d   Lindsley, Craig W ^d   Conn, P Jeffrey ^d   Bolshakov, Vadim Y ^a   Coyle, Joseph T ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSITIVE ALLOSTERIC MODULATOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; VU 0409551; GRM5 PROTEIN, MOUSE; ISOMERASE; OXAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SERINE RACEMASE; VU0409551;

ADULT; ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; FEAR CONDITIONING TEST; GENETIC MODEL; HIPPOCAMPAL SLICE; IN VITRO STUDY; LEARNING DISORDER; MALE; MEMORY DISORDER; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROMODULATION; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HIPPOCAMPUS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALLOSTERIC REGULATION; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONAL PLASTICITY; OXAZOLES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RACEMASES AND EPIMERASES; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84959311405     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.2     Document Type: Article

References (41)

1. Balu DT, Coyle JT (2011a). Glutamate receptor composition of the post-synaptic density is altered in genetic mouse models of NMDA receptor hypo-and hyperfunction. Brain Res 1392: 1-7.
2. Balu DT, Coyle JT (2011b). Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev 35: 848-870.
3. Balu DT, Coyle JT (2012). Neuronal D-serine regulates dendritic architecture in the somatosensory cortex. Neurosci Lett 517: 77-81.
4. Balu DT, Coyle JT (2014). Chronic D-serine reverses arc expression and partially rescues dendritic abnormalities in a mouse model of NMDA receptor hypofunction. Neurochem Int 75C: 76-78.
5. Balu DT, Coyle JT (2015). The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol 20C: 109-115.
6. Balu DT, Li Y, Puhl MD, Benneyworth MA, Basu AC, Takagi S et al (2013). Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci USA 110: E2400-E2409.
7. Basu AC, Tsai GE, Ma CL, Ehmsen JT, Mustafa AK, Han L et al (2009). Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry 14: 719-727.
8. Biber K, Laurie DJ, Berthele A, Sommer B, Tolle TR, Gebicke-Harter PJ et al (1999). Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J Neurochem 72: 1671-1680.
9. Chevaleyre V, Castillo PE (2003). Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38: 461-472.
10. Chevaleyre V, Castillo PE (2004). Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron 43: 871-881.
11. DeVito LM, Balu DT, Kanter BR, Lykken C, Basu AC, Coyle JT et al (2011). Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav 10: 210-222.
12. Doria JG, de Souza JM, Andrade JN, Rodrigues HA, Guimaraes IM, Carvalho TG et al (2015). The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Neurobiol Dis 73: 163-173.
13. Doria JG, Silva FR, de Souza JM, Vieira LB, Carvalho TG, Reis HJ et al (2013). Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease. Br J Pharmacol 169: 909-921.
14. Emamian ES (2012). AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci 5: 33.
15. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P et al (2014). De novo mutations in schizophrenia implicate synaptic networks. Nature 506: 179-184.
16. Gao C, Tronson NC, Radulovic J (2013). Modulation of behavior by scaffolding proteins of the post-synaptic density. Neurobiol Learn Mem 105: 3-12.
17. Hall J, Harris JM, McKirdy JW, Johnstone EC, Lawrie SM (2007). Emotional memory in schizophrenia. Neuropsychologia 45: 1152-1159.
18. Herman EJ, Bubser M, Conn PJ, Jones CK (2012). Metabotropic glutamate receptors for new treatments in schizophrenia. Handb Exp Pharmacol 213: 297-365.
19. Hou L, Klann E (2004). Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent longterm depression. J Neurosci 24: 6352-6361.
20. Kinney JW, Starosta G, Holmes A, Wrenn CC, Yang RJ, Harris AP et al (2002). Deficits in trace cued fear conditioning in galanintreated rats and galanin-overexpressing transgenic mice. Learn Mem 9: 178-190.
21. Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D et al (2012). De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 17: 142-153.
22. Le Bail M, Martineau M, Sacchi S, Yatsenko N, Radzishevsky I, Conrod S et al (2015). Identity of the NMDA receptor coagonist is synapse specific and developmentally regulated in the hippocampus. Proc Natl Acad Sci USA 112: E204-E213.
23. LeDoux JE (2000). Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184.
24. Li Y, Sacchi S, Pollegioni L, Basu AC, Coyle JT, Bolshakov VY (2013). Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level. Nat Commun 4: 1760.
25. Maren S, Phan KL, Liberzon I (2013). The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat Rev Neurosci 14: 417-428.
26. Misane I, Tovote P, Meyer M, Spiess J, Ogren SO, Stiedl O (2005). Time-dependent involvement of the dorsal hippocampus in trace fear conditioning in mice. Hippocampus 15: 418-426.
27. Nickols HH, Conn PJ (2014). Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis 61: 55-71.
28. Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M et al (2012). Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150: 633-646.
29. Puhl MD, Mintzopoulos D, Jensen JE, Gillis TE, Konopaske GT, Kaufman MJ et al (2015). In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia. Neurobiol Dis 73: 269-274.
30. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P et al (2014). A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506: 185-190.
31. Quinn JJ, Loya F, Ma QD, Fanselow MS (2005). Dorsal hippocampus NMDA receptors differentially mediate trace and contextual fear conditioning. Hippocampus 15: 665-674.
32. Raybuck JD, Lattal KM (2014). Bridging the interval: theory and neurobiology of trace conditioning. Behav Process 101: 103-111.
33. Rong R, Ahn JY, Huang H, Nagata E, Kalman D, Kapp JA et al (2003). PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat Neurosci 6: 1153-1161.
34. Rook JM, Xiang Z, Lv X, Ghoshal A, Dickerson JW, Bridges TM et al (2015). Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents. Neuron 86: 1029-1040.
35. Schizophrenia Working Group of the Psychiatric Genomics C (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature 511: 421-427.
36. Strassnig MT, Raykov T, O'Gorman C, Bowie CR, Sabbag S, Durand D et al (2015). Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity. Schizophr Res 165: 76-82.
37. Tsai GE, Lin PY (2010). Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 16: 522-537.
38. Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J et al (2012). Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486: 261-265.
39. Xu J, Antion MD, Nomura T, Kraniotis S, Zhu Y, Contractor A (2014). Hippocampal metaplasticity is required for the formation of temporal associative memories. J Neurosci 34: 16762-16773.
40. Young JW, Geyer MA (2015). Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol 29: 178-196.
41. Younts TJ, Chevaleyre V, Castillo PE (2013). CA1 pyramidal cell theta-burst firing triggers endocannabinoid-mediated long-term depression at both somatic and dendritic inhibitory synapses. J Neurosci 33: 13743-13757.